Cytomegalovirus infection

This phase 3 trial tested an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in healthy people aged 16 to 40. The study enrolled over 7,400 participants, focusing on women who had never been infected with CMV. The vaccine aims to trigger an immune response to …

This trial tests whether the antiviral drug valganciclovir can improve hearing and language outcomes in infants who have hearing loss due to congenital cytomegalovirus (CMV) infection. Infants aged 1 to 12 months with confirmed sensorineural hearing loss will receive either valga…

This trial investigates whether specially grown immune cells, called pathogen-specific cytotoxic T lymphocytes (CTLs), can safely and effectively treat stubborn infections like EBV, CMV, and adenovirus in people with weakened immune systems, such as stem cell or organ transplant …

This early-stage trial is testing whether genetically modified T-cells can safely control viral infections in cancer patients with weakened immune systems. The T-cells are designed to target specific viruses like CMV, BK virus, or COVID-19. The study involves 30 participants and …

This early-stage trial tested whether specially grown immune cells could help transplant patients fight off stubborn viral infections. The study included 8 people who had received a stem cell or organ transplant and had ongoing infections with adenovirus, CMV, or EBV. The approac…

This phase 3 trial tested whether the antiviral drug ganciclovir could prevent reactivation of cytomegalovirus (CMV) in adults with sepsis who needed a breathing machine. The study enrolled 205 CMV-positive patients in the ICU with acute respiratory failure. Participants received…

This study tested a drug called Cytotect, which contains antibodies against the CMV virus, to prevent CMV infection in people who had a stem cell transplant and developed graft-versus-host disease (GVHD). These patients are at high risk for CMV, and current antiviral drugs often …